• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • Experts on Demand
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Precision Cancer Therapeutics Market, 2022

$5,000.00 – $10,000.00

Clear
SKU: 22-719 Category: Pharmaceuticals Market Research Tags: Angiogenesis inhibitors, Cancer, CAR-T therapies, Kinase inhibitors, Monoclonal antibodies, pharmaceuticals, precision cancer, Proteasome inhibitors Pages: 154
  • Description
  • Table of Contents
  • Latest reports

Description

Despite advances in cancer treatment, cancer continues to affect about 18.1 million people annually, generating a significant loss of life, financial burden and overall strain on the health industry.  Worldwide between 35 and 40 million people are living with cancer and nearly 10 million people lose the battle annually.  The most common cancers affecting the world population include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder. Cancer deaths occur in about 50% of people who develop cancer in developed countries; this is in contrast to 80% death rate in cancer patients in underdeveloped countries.

Precision treatments are less invasive and less damaging to the body, and they promise improved outcomes in many cases.

The demand for more effective and tolerable cancer treatments has led to the development of novel therapeutic agents that specifically target the malignant cells. Today, advanced precision cancer therapies are available, and more are being developed each year.  Although there are some older precision therapies on the market, the industry is now expanding the use of these treatments to better treat cancer victims.  Precision treatments are less invasive and less damaging to the body, and they promise improved outcomes in many cases.

This report Precision Cancer Therapeutics Market, 2022 specifically focuses on five leading segments of precision therapies:

  • Monoclonal antibodies
  • Kinase inhibitors
  • Angiogenesis inhibitors
  • Proteasome inhibitors
  • CAR-T therapies
  • Other precision therapies

Additionally, smaller areas of precision therapies are covered including mTOR inhibitors, PI3K inhibitors, PARP inhibitors, apoptosis inhibitors, histone deacetylase inhibitors, CDK inhibitors, hedgehog signaling pathway inhibitors and several others.

Scope and Methodology

Kalorama Information has watched the cancer treatment market evolve over the past two decades and evaluated the impact new technologies are making on the market.  Precision Cancer Therapeutics, 2022 focuses on the expanding area of precision cancer therapies and includes current products available and discusses some of the most exciting developments in progress.

This report covers precision cancer therapies that do at least one of the following:

  • Block or turn off chemical signals that tell the cancer cell to grow and divide
  • Change proteins within the cancer cells so the cells die
  • Stop making new blood vessels to feed the cancer cells
  • Trigger the immune system to kill the cancer cells
  • Carry toxins to the cancer cells to kill them, but not normal cells

The report includes statistical information for cancers by type on a global level.  Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled.  The market segments provide an overview of disease epidemiology, leading product sales, market estimates and forecasts, and competitive summary of leading providers.  The report also includes a list of Phase 3 precision therapies in development. Throughout the report, several market indicators, trends and barriers are discussed.

The following are companies of focus in the report:

  • AbbVie
  • Astellas Pharma U.S., Inc
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Clovis Oncology, Inc.
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly & Company
  • EMD Serono, Inc. (Merck KgaA)
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer, Inc.
  • Puma Biotechnology, Inc.
  • Roche (F. Hoffman-La Roche, Ltd.)
  • Sanofi/Genzyme
  • Seagen Inc.
  • Takeda

 

Table of Contents

Chapter 1: Executive Summary

Overview

Scope and Methodology

Market Overview and Analysis

  • Figure 1-1: Global Precision Cancer Therapeutic Market Size and Forecast, 2017-2027 ($millions)

 

Chapter 2: Introduction

Global Cancer Burden

  • Figure 2-1: Incidence of Cancer by Type, 2020
  • Figure 2-2: Distribution of Cancer Incidence by Type, 2020

Introduction to Cancer

Biochemistry of Cancer Cells

Causes of Cancer Growth May Shed Light on Treatment

Environmental Factors, DNA, RNA

  • Table 2-1: Virus Association with Human Cancer

Cellular Oncogenes

Tumor Suppressor Genes

Cancer Treatment Approaches

  • Table 2-2: Characteristics of Cancer Treatment Approaches (chemotherapy, hormone therapy, Precision therapy)

What is Precision Cancer Therapy?

Trends in Research and Development of Precision Cancer Therapeutics

Monoclonal Antibodies: The Leading Area of Cancer Precision Therapy

 

Chapter 3: Precision Cancer Therapies: Monoclonal Antibodies

Monoclonal Antibody Overview

Market Outlook

  • Figure 3-1: Cancer Monoclonal Antibody Market, 2017-2027 ($ millions)

Principal Products

  • Table 3-1: Top 10 Cancer Indicated Monoclonal Antibodies, 2021 and 2022 Sales (millions $)
  • Figure 3-2: Top 10 Cancer Indicated Monoclonal Antibodies, 2021 and 2022 Sales (millions $)

Avastin (bevacizumab)

Blincyto (blinatuomab)

Darzalex (daratumumab)

Erbitux (cetuximab)

Herceptin (trastuzumab)

Kadcyla (ado-trastuzumab emtansine)

Keytruda (pembrolizumab)

Libtayo (cemiplimab-rwlc)

Opdivo (nivolumab)

Padcev (enfortumab vedotin-jfv)

Perjeta (pertuzumab)

Rituxan (rituximab)

Sarclisa (isatuximab)

Tivdak (tisolumab vedotin-tftv)

Tecentriq (atezolizumab)

Vectibix (panitumumab)

Xgeva (denosumab)

Yervoy (ipilimumab)

  • Table 3-2: Selected Monoclonal Antibodies in Cancer Therapy

Late-Stage Monoclonal Antibodies Development

  • Table 3-3: Selected Late-Stage Monoclonal Antibodies in Phase 3 Development

Market Breakdown of Monoclonal Antibodies

Cancer Monoclonal Antibody Market by Target

  • Table 3-4: Cancer Monoclonal Antibody Market by Target, 2022 and Forecast 2027  ($ millions)
  • Figure 3-3: Cancer Monoclonal Antibody Market by Target, 2022 and Forecast 2027 ($ millions)
  • Figure 3-4: Cancer Monoclonal Antibody Market Distribution by Target, 2022 (%)
  • Figure 3-5: Cancer Monoclonal Antibody Market Distribution by Target, 2027 (%)

Cancer Monoclonal Antibody Market by Type

  • Figure 3-6: Development of the mAb Cancer Treatment Market, 2010-2027 ($ millions)
  • Table 3-5: Cancer Treatment mAb Market by Type, 2022-2027 ($ millions)
  • Figure 3-7: Monoclonal Antibody Market by Cancer Type, 2022 and 2027 ($ millions)
  • Figure 3-8: Monoclonal Antibody Market, Distribution by Cancer Type, 2022 (%)
  • Figure 3-9: Monoclonal Antibody Market Distribution by Indication, 2027 (%)

Regional Market Summary

  • Figure: 3-10: Cancer Monoclonal Antibody Market Summary by Geographic Region, 2022 and 2027  ($ millions)

Competitor Summary

Merck & Co.

Genentech/Roche

Bristol-Myers Squibb

Janssen Biotech/J&J

Amgen

AstraZeneca

EMD Serono

  • Table 3-6: Cancer Monoclonal Antibody Competitor Market Share – Top Seven, 2022 ($ millions)

 

Chapter 4: Precision Cancer Therapies: Kinase Inhibitors

Kinase Inhibitor Overview

Market Outlook

  • Figure 4-1: Kinase Inhibitor Market, 2022-2027: CAGR 8.8% ($ millions)

Principal Products

  • Table 4-1: Top 10 Cancer Indicated Kinase Inhibitors, 2021 and Forecast 2022 Sales  (millions $)
  • Figure 4-2: Top 10 Cancer Indicated Kinase Inhibitors, 2021 and Forecast 2022 Sales (millions $)

Alecensa (alectinib)

Alunbrig (brigatinib)

Imbruvica (ibrutinib)

Inlyta (axitinib)

Sprycel (dasatinib)

Tasigna (nilotinib)

Tagrisso (osimertinib)

Gleevec (imatinib)

Mekinist+Tafinlar (trametinib + dabrafenib)

Sutent (sunitinib)

Jakafi/Jakavi (ruxolitinib)

Nexavar (sorafenib)

Tukysa (tucatinib)

Votrient (pazopanib)

  • Table 4-2: Kinase Inhibitors in Cancer Therapy

Late-Stage Kinase Inhibitors Development

  • Table 4-3: Selected Phase 3 Kinase Inhibitors in Development

Market Breakdown of Kinase Inhibitors

Cancer Kinase Inhibitor Market by Target

  • Table 4-4: Cancer Kinase Inhibitor Market by Target, 2022 and Forecast 2027 ($ millions)
  • Figure 4-3: Cancer Kinase Inhibitor Market by Target, 2022 and 2027 ($ millions)
  • Figure 4-4: Kinase Inhibitor Market Distribution by Target, 2022 (%)
  • Figure 4-5: Kinase Inhibitor Market Distribution by Target, 2027 (%)

Cancer Kinase Inhibitor Market by Type

  • Figure 4-6: Development of the Kinase Inhibitor Cancer Treatment Market, 2010-2027 ($ millions)
  • Table 4-5: Cancer Treatment Kinase Inhibitor Market by Type, 2022-2027 ($ millions)
  • Figure 4-7: Kinase Inhibitor Market by Cancer Indication, 2022 and 2027 ($ millions)
  • Figure 4-8: Kinase Inhibitor Market Distribution by Cancer Indication, 2022 (%)
  • Figure 4-9: Kinase Inhibitor Market Distribution by Cancer Indication, 2027 (%)

Regional Market Summary

  • Figure: 4-10: Cancer Kinase Inhibitor Market Summary by Geographic Region, 2022 and 2027 ($ millions)

Competitor Summary

Novartis

AstraZeneca

AbbVie

Johnson & Johnson

Pfizer

Bristol-Myers Squibb

Roche/Genentech

  • Table 4-6: Cancer Kinase Inhibitor Competitor Market Share, 2022 ($ millions)

 

Chapter 5: Precision Cancer Therapies: Angiogenesis Inhibitors

Angiogenesis Inhibitor Overview

Market Outlook

  • Figure 5-1: Angiogenesis Inhibitor Market, 2017-2027 ($ millions)

Principal Products

Pomalyst/Imnovid (pomalidomide)

Revlimid (lenalidomide)

Thalomid (thalidomide)

Zaltrap (ziv-aflibercept)

  • Table 5-1: Angiogenesis Inhibitors in Cancer Therapy

Late-Stage Angiogenesis Inhibitor Phase 3 Development

  • Table 5-2: Selected Phase 3 Angiogenesis Inhibitor Development

Regional Market Summary

  • Figure: 5-2: Cancer Angiogenesis Inhibitor Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)

Competitor Summary

 

Chapter 6: Precision Cancer Therapies: CAR-T Therapies

CAR-T Overview

Manufacturing Process for CAR-T

Leukapheresis

Activation

Transduction

Expansion

Regulatory Developments

Market Outlook

  • Figure 6-1: CAR-T Market, 2017-2027 ($ millions)

Principal Products

Abecma

Breyanzi

Carvykti

Kymriah

Tecartus

Yescarta

Late-Stage CAR-T Therapies Development

  • Table 6-1:  Phase III Development ¾ CAR-T Therapies, Select Projects

Regional Market Summary

  • Figure: 6-2: Cancer CAR-T Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)

Competitor Summary

 

Chapter 7: Precision Cancer Therapies: Proteasome Inhibitors

Proteasome Inhibitor Overview

Market Outlook

  • Figure 7-1: Proteasome Inhibitor Market, 2022-2027 ($ millions)

Principal Products

Kyprolis (carfilzomib)

Ninlaro (ixazomib)

Velcade (bortezomib)

  • Table 7-1: Proteasome Inhibitors in Cancer Therapy

Regional Market Summary

  • Figure 7-2: Cancer Proteasome Inhibitor Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)

Competitor Summary

Takeda

Amgen

  • Table 7-2: Cancer Proteasome Inhibitor Competitor Market Share, 2022 ($ millions)

 

Chapter 8: Precision Cancer Therapies: Other Precision Therapies

Other Precision Therapies Overview

Market Outlook

  • Figure 8-1: Other Precision Therapies Market, 2017-2027 ($ millions)

Principal Products

mTOR Inhibitor ¾ Afinitor (everolimus)

mTOR Inhibitor ¾ Torisel (temsirolimus)

PI3K Inhibitor ¾ Zydelig

PARP Inhibitor ¾ Lynparza

PARP Inhibitor ¾ Zejula

Apoptosis Inducer ¾ Venclexta

CDK Inhibitors – Ibrance (palbociclib)

CDK Inhibitors – Kisqali (ribociclib)

  • Table 8-1: Other Precision Cancer Therapies

Late-Stage Other Therapies Development

  • Table 8-2: Select Phase 3 Other Therapies Development

Regional Market Summary

  • Figure: 8-2: Other Precision Therapies Market Summary by Geographic Region, Estimated 2022 and 2027  ($ millions)

 

Chapter 9: Market Summary

Market Influences

Global Demographics

  • Table 9-1: Global Population, through 2050 (population in millions)

Aging Population

  • Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050

Cancer: A Growing Economic Burden

Cost Containment

  • Table 9-2: The Cost of Monoclonal Antibodies (2020-2021)

Reimbursement Landscape: A Deciding Factor for Success

The Biosimilar Movement

Regional Market Overview

  • Table 9-3: Precision Cancer Therapeutics Market Summary by Geographical Region, 2022-2027 ($ millions)

United States and Canada

  • Table 9-4: Precision Cancer Therapeutics Market Summary for U.S. and Canada, 2022-2027 ($ millions)
  • Figure 9-2: Precision Cancer Therapeutics for U.S. and Canada, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 %

EMEA

  • Table 9-5: Precision Cancer Therapeutics Market Summary for EMEA, 2022-2027 ($ millions)
  • Figure 9-3: Precision Cancer Therapeutics for EMEA, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)

Asia Pacific

  • Table 9-6: Precision Cancer Therapeutics Market Summary for Asia Pacific, 2022-2027 ($ millions)
  • Figure 9-4: Precision Cancer Therapeutics for Asia Pacific, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)

Latin America

  • Table 9-7: Precision Cancer Therapeutics Market Summary for Latin America, 2022-2027 ($ millions)
  • Figure 9-5: Precision Cancer Therapeutics for Latin America, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)

 

Chapter 10: Market Participants

Top 15 Overview

  • Table 10-1: Global Market Participants for Precision Cancer Therapeutics, Top 15 Companies, 2022 ($ in millions)
  • Figure 10-1: Global Market Share for Precision Cancer Therapeutics, 2022 %
  • Figure 10-2: Growth in Precision Cancer Therapeutics by Company 2010 vs. 2022 ($ in millions)
  • Figure 10-3: Growth Trend by Company, 2010-2022 CAGR: Precision Cancer Therapeutics

AbbVie, Inc.

  • Table 10-2: AbbVie Corporate Summary

Company Summary

Amgen

  • Table 10-3: Amgen Corporate Summary

Company Summary

Astellas Pharma U.S., Inc

  • Table 10-4: Astellas Corporate Summary

Company Summary

AstraZeneca PLC

  • Table 10-5: AstraZeneca Corporate Summary

Company Summary

Bayer AG

  • Table 10-6: Bayer Corporate Summary

Company Summary

Bristol-Myers Squibb Company

  • Table 10-7: Bristol-Myers Squibb Corporate Summary

Company Summary

Clovis Oncology, Inc.

  • Table 10-8: Clovis Oncology Corporate Summary

Company Summary

Dendreon Pharmaceuticals LLC

  • Table 10-9: Dendreon Corporate Summary

Company Summary

Eli Lilly & Company

  • Table 10-10: Eli Lilly Corporate Summary

Company Summary

EMD Serono, Inc. (Merck KgaA)

  • Table 10-11: EMD Serono Corporate Summary

Company Summary

Eisai Co., Ltd.

  • Table 10-12: Eisai Corporate Summary

Company Summary

Exelixis, Inc.

  • Table 10-13: Exelixis Corporate Summary

Company Summary

Gilead Sciences, Inc.

  • Table 10-14: Gilead Sciences Corporate Summary

Company Summary

GlaxoSmithKline

  • Table 10-15: GSK Corporate Summary

Company Summary

Johnson & Johnson

  • Table 10-16: Johnson & Johnson Corporate Summary

Company Summary

Merck & Co., Inc.

  • Table 10-17: Merck & Co. Corporate Summary

Company Summary

Novartis AG

  • Table 10-18: Novartis Corporate Summary

Company Summary

Otsuka Holdings Co., Ltd.

  • Table 10-19: Otsuka Corporate Summary

Company Summary

Pfizer, Inc.

  • Table 10-20: Pfizer Corporate Summary

Company Summary

Puma Biotechnology, Inc.

  • Table 10-21: Puma Biotechnology Corporate Summary

Company Summary

Roche (F. Hoffman-La Roche, Ltd.)

  • Table 10-22: Roche Corporate Summary

Company Summary

Sanofi/Genzyme

  • Table 10-23: Sanofi/Genzyme Corporate Summary

Company Summary

Seagen Inc.

  • Table 10-24: Seagen Corporate Summary

Company Summary

Takeda Oncology – Millennium Pharmaceuticals

  • Table 10-25: Takeda Oncology Corporate Summary

Company Summary

 

    Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals
    May 22, 2023
    Precision Cancer Therapeutics Market, 2022
    October 25, 2022
    The World Market for Vaccines, 2022-2027
    September 23, 2022
    Biopharmaceutical Contract Manufacturing Organization (BCMO) Market, 2022
    August 2, 2022

Related products

  • Placeholder image

    World Market for Anti-infectives Volume II: The World Market for Antibacterial Medications, The

    $2,500.00 – $5,000.00
  • Placeholder image

    Cardiovascular Disease: The 45 Market in the United States for Drugs and Medical Devices

    $2,995.00 – $5,990.00
  • Placeholder image

    Market for Generic Biologics: Issues, Trends, and Market Potential, The

    $1,500.00 – $3,000.00
  • Placeholder image

    OTC Women’s Health: A Supplement to Women’s Health, 3rd Edition

    $1,496.00 – $2,992.00

Contact Us

  •  Email Us: Customer Service

  •  Phone (US):  703-778-3080

  •  Fax:  703-778-3081

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • Global Medtech Sales Exceed $500 Billion as Chronic Diseases Shape Market’s Future November 14, 2023
  • Healthcare Advances, Investments Support Laboratory Information System (LIS) Growth October 26, 2023
  • Personalized Medicine Key to IVD Procedure Volumes’ 10% Annual Growth October 19, 2023
  • RNA Sequencing: Life Sciences’ Transformative $2.6 Billion Industry October 4, 2023
  • How Globalization and Climate Change Impact COVID-19 and the IVD Market September 20, 2023

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
In Vitro Diagnostics (IVD) in Malaysia, Singapore and Indonesia, 2022 The World Market for Molecular Diagnostics Tests, 11th Edition
Scroll to top